Horizon Discovery Group plc Board Change (7054G)
08 November 2018 - 6:01PM
UK Regulatory
TIDMHZD
RNS Number : 7054G
Horizon Discovery Group plc
08 November 2018
Horizon Discovery Group plc
Board Change
Cambridge, UK, 8 November 2018: Horizon Discovery Group plc
(LSE: HZD) ("Horizon" or "the Group"), a global leader in the
application of gene editing and gene modulation technologies, today
announces the appointment of Margarita Krivitski as Non-Executive
Director, with immediate effect.
Ms. Krivitski is a Vice President at ValueAct Capital
Management, L.P. ("ValueAct Capital"), a San Francisco based
investment firm. Prior to joining ValueAct Capital in September
2015, Ms. Krivitski worked at TPG Capital in the North American
Buyout Group, focusing on investments across the healthcare
industry. Prior to TPG Capital, Ms. Krivitski worked as an
investment banker at Goldman Sachs in New York. She received a B.A.
in Applied Mathematics from Harvard University.
ValueAct Capital is a key shareholder in Horizon, currently
holding 13.3%. ValueAct has invested in Horizon Discovery through
the ValueAct Spring Fund, a fund focused on making long term,
concentrated investments in companies that are responsibly and
creatively addressing environmental and social problems.
Dr Ian Gilham, Non-Executive Chairman of Horizon Discovery,
commented: "I am pleased to welcome Margarita Krivitski to the
Board of Horizon Discovery. We have engaged closely with ValueAct
Capital and Margarita over recent months and are excited that they
share our long term vision for growth and value creation. We look
forward to Margarita's participation as we execute our recently
announced five-year strategic plan."
Margarita Krivitski, incoming Non-Executive Director at Horizon
Discovery, commented: "I have been deeply impressed by Horizon's
long-standing expertise in gene editing and the value that their
products and services bring to customers, helping them advance
scientific knowledge and discover novel therapeutics. I look
forward to working closely with the Board and management team as
they execute their strategic plan and drive long term value
creation for all stakeholders."
Save as disclosed below, Horizon confirms that there are no
further disclosures to be made in relation to Rule 17 of paragraph
(g) of Schedule Two of the AIM Rules for Companies in respect of
Margarita Krivitski's appointment.
Ms Margarita Krivitski is aged 29 and was formerly known as
Margarita Krivitskaya.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker HZD
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFKODBBBDBKDK
(END) Dow Jones Newswires
November 08, 2018 02:01 ET (07:01 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024